SCHEMBL29919404

SCHEMBL29919404

CCC(=O)Nc1ccccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 8/20 0.46
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MAPK1 P28482 2/20 0.42
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 3/20 0.40
GAA P10253 1/20 0.40
HIF1A Q16665 1/20 0.39
PARP14 Q460N5 1/20 0.39
AHR P35869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17699718 0.87 MAPT (0.39) LIPEALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL29782639 0.87 MAPT (0.39) LIPEALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL15502141 0.87 LIPE (0.45) LIPEALDH1A1SMN1; SMN2MAPK1KDM4E
SCHEMBL26674648 0.85 TSHR (0.58) LIPEALDH1A1MAPK1HPGDKDM4E
SCHEMBL1797092 0.84 LIPE (0.49) LIPEALDH1A1SMN1; SMN2MAPK1HPGD
SCHEMBL29895467 0.84 LIPE (0.49) LIPEALDH1A1SMN1; SMN2MAPK1HPGD
SCHEMBL1058987 0.83 LIPE (0.48) LIPEALDH1A1NPC1RAB9AHPGD
SCHEMBL11894946 0.83 GAA (0.49) LIPEMAPK1GAA
SCHEMBL29269315 0.79 CETP (0.49) LIPEALDH1A1RAB9AKDM4ELMNA
SCHEMBL16100601 0.78 LIPE (0.45) LIPEMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022216655-A1 N-(6-((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YI)AMINO)PYRIDAZIN-3-YL)PHENYL)CARBOXAMIDE AND (6- ((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)BENZAMIDE DERIVATIVES AS MACHR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS VANDERBILT UNIVERSITY (US) 2022-10-13 WO disclosed